Cancer Neuroscience of Brain Tumors
TBC
TBC
Show more
TBC
Frank Winkler
Frank Winkler grew up in Hamburg, where he attended the Wilhelm-Gymnasium. After graduating from high school, he studied human medicine at the University of Hamburg with stays in Freiburg, Cape Town and London at the National Hospital for Neurology and Neurosurgery.
In 1999, he began his training at the Neurological Clinic, Großhadern Hospital of the Ludwig Maximilian University of Munich. From 2002 to 2004, he completed a post-doctoral programme at Harvard University. During this time, he conducted research on the influence of the vascular system on brain tumours.
Show more
In 2012, he was appointed professor of Experimental Neuro-Oncology at the Department of Neurology in Heidelberg, where he has been senior physician since 2014. His Experimental Neuro-Oncology research group is based at the German Cancer Research Centre (DKFZ) in Heidelberg. His wife Eva Winkler is a specialist in haematology/oncology at Heidelberg University Hospital and a member of the German Ethics Council.
The laboratory led by Frank Winkler has used neuroscience methods to develop a new understanding of malignant adult brain tumours, glioblastomas and brain metastases. Key discoveries from this work have helped to establish the new field of cancer neuroscience research. These include malignant multicellular tumour networks that are highly functional and resilient and driven by developmental neurobiological factors, including pacemaker-like tumour cells in network nodes and excitatory synapses between brain neurons and various incurable brain tumour entities that drive brain tumour growth, invasion, and metastasis.
Frank Winkler has initiated clinical trials investigating how brain tumours in humans can be better controlled by disrupting neuro-cancer networks.
More information can be found on Wikipedia.
Frank Winkler grew up in Hamburg, where he attended the Wilhelm-Gymnasium. After graduating from high school, he studied human medicine at the University of Hamburg with stays in Freiburg, Cape Town and London at the National Hospital for Neurology and Neurosurgery.
In 1999, he began his training at the Neurological Clinic, Großhadern Hospital of the Ludwig Maximilian University of Munich. From 2002 to 2004, he completed a post-doctoral programme at Harvard University. During this time, he conducted research on the influence of the vascular system on brain tumours.
Show more
In 2012, he was appointed professor of Experimental Neuro-Oncology at the Department of Neurology in Heidelberg, where he has been senior physician since 2014. His Experimental Neuro-Oncology research group is based at the German Cancer Research Centre (DKFZ) in Heidelberg. His wife Eva Winkler is a specialist in haematology/oncology at Heidelberg University Hospital and a member of the German Ethics Council.
The laboratory led by Frank Winkler has used neuroscience methods to develop a new understanding of malignant adult brain tumours, glioblastomas and brain metastases. Key discoveries from this work have helped to establish the new field of cancer neuroscience research. These include malignant multicellular tumour networks that are highly functional and resilient and driven by developmental neurobiological factors, including pacemaker-like tumour cells in network nodes and excitatory synapses between brain neurons and various incurable brain tumour entities that drive brain tumour growth, invasion, and metastasis.
Frank Winkler has initiated clinical trials investigating how brain tumours in humans can be better controlled by disrupting neuro-cancer networks.
More information can be found on Wikipedia.
Read the Abstracts from Our Invited Speakers
Cancer Biology
- AllergoOncology: Lessons Learned from the Allergy-Glioblastoma Connection
Aurélie Poli, Luxembourg Institute of Health, LUXEMBOURG
- Cytotoxic NK Cells Impede Response to Checkpoint Immunotherapy in Melanoma with an Immune-Excluded Phenotype
Joanna Poźniak, KU Leuven, BELGIUM
- Inducing Immunogenic Tertiary Lymphoid Structures Across Cancer Types With Dendritic Cell Reprogramming
Camille Chatelain, Lund University, SWEDEN
- The Role of ILC2 in Tissue Homeostasis and Neoplasia
Tim Halim, Cancer Research UK Cambridge Institute, UNITED KINGDOM
Cancer Neuroscience
- Latent Neuropathy in Colorectal Cancer: Implications for Cancer Survivorship
Andrew Shepherd, University of Texas MD Anderson Cancer Center, USA
- Remodelling of the Bone Microenvironment During Cancer Infiltration: Insights from Multiplex Imaging and Spatial Transcriptomics
Christina Møller Andreasen, University of Southern Denmark, DENMARK
- Enteric Nervous System-Derived VIP Restrains Differentiation of LGR5+ Stem Cells Towards the Secretory Lineage Impeding Type 2 Immune Programs
Christoph Klose, Charité – Berlin University Medicine, GERMANY
Cancer Therapy
- Targeting the Dark Matter of Cancer with AI-Designed Mini Binder
Tobias Bald, University of Bonn, GERMANY
- Engineering Nanomedicines for Targeted Neuroimmune Modulation
Helena Florindo, University of Lisbon, PORTUGAL
- Potentiating Immunotherapy of Urological Cancers with Oncolytic Viruses
Gabri van der Pluijm, Leiden University Medical Center, THE NETHERLANDS
- Cancer Neuroscience of Brain Tumors: From Basic Discoveries to Clinical TrialsKEYNOTE SPEAKER
Frank Winkler, Universitätsklinik Heidelberg, GERMANY
- TBC
Sheeba Irshad, King’s College London, UNITED KINGDOM
- The War Against Glioblastoma Needs More Than Standard of Care
Stefaan Van Gool, IOZK Immun-Onkologisches Zentrum Köln, GERMANY
- Uncovering the Spatial Regulation of γδ T Cells: Toward Receptor-Guided Immunotherapy
Jürgen Kuball, University Medical Center Utrecht, THE NETHERLANDS
- Latest Advances in CAR‑T Therapy in Lymphoma: Where Are We and Where Are We Going?
Jarosław Dybko, Lower Silesian Oncology Center in Wroclaw, POLAND
- Expanding CAR Targets to Non Protein Antigens
Sébastien Wälchli, Oslo University Hospital, NORWAY
- TBC
Helen Kakkassery, King’s College London, UNITED KINGDOM
PORT for Business — Company Session
- From Sample to Insight: Advanced Analytics for Oncology Research
Malwina Woźniak, Łukasiewicz – PORT, POLAND
- Beyond glioblastoma — WPD Pharmaceuticals
Mariusz Olejniczak, WPD Pharmaceuticals, POLAND
- The Development of USP7 Inhibitor for Cancer Immunotherapy
Zbigniew Zasłona, Molecule, POLAND
- Leveraging Cancer Biology for Therapeutic Innovation: Clinical and Discovery Advances at Ryvu
Milena Mazan, Ryvu Therapeutics, POLAND
- TBC
Marek Kudła, Ardigen, POLAND
- TBC
Artur Wnorowski, Biotechna, POLAND
- Development of Biological Drugs for Oncological Indications at Mabion
Jakub Knurek, Mabion, POLAND